Core Insights - Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, will present new data on multiple hematologic malignancies at the American Society of Hematology (ASH) Annual Meeting from December 6-9 [1] - The data will emphasize Merck's commitment to advancing clinical research in hematology and its diverse pipeline of investigational candidates [1] Company Focus - Merck is actively involved in clinical research related to hematologic malignancies, showcasing its expanding pipeline of investigational candidates [1] - The presentation at ASH reflects the company's ongoing efforts to contribute to advancements in the field of hematology [1]

Core Insights - Ascentage Pharma announced that 13 studies of its key assets will be presented at the 2025 European Hematology Association Annual Congress in Milan, Italy, from June 12-15, 2025 [1][2] Group 1: Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancers, with a rich pipeline of innovative drug candidates [9] - The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for specific types of chronic myeloid leukemia (CML) [10] - The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for treating various hematologic malignancies, with an NDA accepted for priority review in China [11] Group 2: Research Presentations - The congress will feature an oral presentation on integrating genomic and transcriptomic insights for predicting responses in patients with chronic myeloid leukemia (CML) [3] - Multiple poster presentations will include studies on the combination of olverembatinib with other therapies for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [4][5] - Online publications will cover various studies, including the efficacy and safety of olverembatinib in relapsed and persistent minimal residual disease positive Ph+ ALL patients [6][8]